Chai Discovery, an artificial intelligence drug-discovery company backed by Sam Altman’s OpenAI, has secured $130 million ...

This figure illustrates three key applications of AI in antimicrobial drug development: (1) target identification and validation, including novel target discovery, affinity prediction, multi-target ...

After a year of progress, scientists say they are on the cusp of turning AI-designed antibodies into potential therapies. In ...

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...

After reportedly flirting with going public for years, the artificial intelligence-powered drug developer Insilico Medicine ...

In a university lab, an AI system generated millions of novel molecules to fight drug-resistant infections. And they’re working. Inside a lab at the Massachusetts Institute of Technology late last ...

Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...

An MIT team used artificial intelligence to design novel antibiotics, two of which showed promise against MRSA and gonorrhea. With help from artificial intelligence, MIT researchers have designed ...

The study introduces a three-circle convergence framework, AI, smart functionality and sustainability, demonstrating that the ...

This story is part of Fast Company’s 2025 Innovation by Design Awards. Explore the full list of companies creating products, reimagining spaces, and working to design a better world. Read more about ...